{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:17:03Z","timestamp":1788347823608,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01575-y","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:53:16Z","timestamp":1788346396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1575_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1575_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"1575_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"1575_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"1575_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437\u201348.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1575_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"1575_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1200\/JCO.2020.38.4_suppl.297","volume":"38","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Nagashima H, Fujikawa K, et al. Improved efficacy to cytotoxic agents chemotherapy after immune checkpoint inhibitors exposure in metastatic gastric cancer. J Clin Oncol. 2020;38(4 Suppl):297. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.297.","journal-title":"J Clin Oncol"},{"key":"1575_CR8","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/esmoopen-2020-000775","volume":"5","author":"A Sasaki","year":"2020","unstructured":"Sasaki A, Kawazoe A, Eto T, et al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 2020;5:e000775. https:\/\/doi.org\/10.1136\/esmoopen-2020-000775.","journal-title":"ESMO Open"},{"key":"1575_CR9","doi-asserted-by":"publisher","first-page":"102071","DOI":"10.1016\/j.esmoop.2023.102071","volume":"8","author":"Y Narita","year":"2023","unstructured":"Narita Y, Shoji H, Kito Y, et al. Chemotherapy after nivolumab for advanced gastric cancer: REVIVE study, a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. ESMO Open. 2023;8:102071.","journal-title":"ESMO Open"},{"key":"1575_CR10","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.21037\/jgo-23-598","volume":"14","author":"Y Jeon","year":"2023","unstructured":"Jeon Y, Rha SY. The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer. J Gastrointest Oncol. 2023;14:2347\u201357.","journal-title":"J Gastrointest Oncol"},{"key":"1575_CR11","doi-asserted-by":"publisher","first-page":"28841","DOI":"10.1038\/s41598-025-13714-9","volume":"15","author":"T Matsumoto","year":"2025","unstructured":"Matsumoto T, Ikoma T, Makiyama C, et al. Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab. Sci Rep. 2025;15:28841. https:\/\/doi.org\/10.1038\/s41598-025-13714-9.","journal-title":"Sci Rep"},{"key":"1575_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-20-3559","volume":"27","author":"TE Nakajima","year":"2021","unstructured":"Nakajima TE, Kadowaki S, Minashi K, et al. Multicenter phase I\/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27:1029\u201336.","journal-title":"Clin Cancer Res"},{"key":"1575_CR13","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Yanez P, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (KEYNOTE-811): interim analyses from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"1575_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"1575_CR15","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"1575_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"issue":"12","key":"1575_CR17","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.clinthera.2017.10.017","volume":"39","author":"S Saito","year":"2017","unstructured":"Saito S, Muneoka Y, Ishikawa T, Akazawa K. Cost-effectiveness of paclitaxel plus ramucirumab combination therapy for advanced gastric cancer progressing after first-line chemotherapy in Japan. Clin Ther. 2017;39(12):2380\u20138.","journal-title":"Clin Ther"},{"issue":"12","key":"1575_CR18","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40273-017-0528-y","volume":"35","author":"NC B\u00fcy\u00fckkaramikli","year":"2017","unstructured":"B\u00fcy\u00fckkaramikli NC, Blommestein HM, Riemsma R, et al. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an Evidence Review Group perspective of a NICE single technology appraisal. PharmacoEconomics. 2017;35(12):1211\u201321.","journal-title":"PharmacoEconomics"},{"issue":"5","key":"1575_CR19","doi-asserted-by":"publisher","first-page":"e0232240","DOI":"10.1371\/journal.pone.0232240","volume":"15","author":"S Li","year":"2020","unstructured":"Li S, Peng L, Tan C, et al. Cost-effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 2020;15(5):e0232240.","journal-title":"PLoS ONE"},{"issue":"8","key":"1575_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14796694.2026.2642222","volume":"22","author":"H Kawakami","year":"2026","unstructured":"Kawakami H, Tanizawa Y, Shimizu T. Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan. Future Oncol. 2026;22(8):969\u201380. https:\/\/doi.org\/10.1080\/14796694.2026.2642222.","journal-title":"Future Oncol"},{"key":"1575_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","volume":"121","author":"K Saleh","year":"2019","unstructured":"Saleh K, Daste A, Martin N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123\u20139.","journal-title":"Eur J Cancer"},{"key":"1575_CR22","doi-asserted-by":"publisher","first-page":"1458479","DOI":"10.3389\/fonc.2024.1458479","volume":"14","author":"S Llop","year":"2024","unstructured":"Llop S, Lorente D, Iglesias L, et al. Salvage chemotherapy after progression on immunotherapy in recurrent\/metastatic squamous cell head and neck carcinoma. Front Oncol. 2024;14:1458479.","journal-title":"Front Oncol"},{"key":"1575_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017;112:90\u20135.","journal-title":"Lung Cancer"},{"key":"1575_CR24","first-page":"18","volume":"146","author":"M Bersanelli","year":"2020","unstructured":"Bersanelli M, Minari R, Gnetti L, et al. Chemotherapy in non-small cell lung cancer patients after prior treatment with immune checkpoint inhibitors. Lung Cancer. 2020;146:18\u201326.","journal-title":"Lung Cancer"},{"key":"1575_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2022.08.014","volume":"175","author":"L Meynard","year":"2022","unstructured":"Meynard L, Dinart D, Delaunay B, et al. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma. Eur J Cancer. 2022;175:43\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.014.","journal-title":"Eur J Cancer"},{"issue":"19","key":"1575_CR26","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3(19):e59125. https:\/\/doi.org\/10.1172\/jci.insight.59125.","journal-title":"JCI Insight"},{"issue":"3","key":"1575_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215\u201333. https:\/\/doi.org\/10.1038\/nrd3626.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1575_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-018-0403-1","volume":"6","author":"Y Tada","year":"2018","unstructured":"Tada Y, Togashi Y, Kotani D, et al. Targeting VEGFR2 with ramucirumab strongly impacts effector\/activated regulatory T cells and CD8\u2009+\u2009T cells in the tumor microenvironment. J Immunother Cancer. 2018;6(1):106. https:\/\/doi.org\/10.1186\/s40425-018-0403-1.","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01575-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:53:17Z","timestamp":1788346397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01575-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01575-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"206"}}